Corporate Fact Sheet FINAL - MAKO Surgical Corp.

Fact Sheet
MAKO Surgical Corp. (NASDAQ: MAKO)
Corporate Headquarters:
2555 Davie Road
Ft. Lauderdale, FL 33317
Phone: 866.647.6256
Fax: 954.927.0446.
makosurgical.com
makoplasty.com
Founded: November 2004
Initial Public Offering: February 2008
Number of Employees: Over 400
Mission: MAKO Surgical Corp. is dedicated to advancing orthopedics through the discovery and
development of quality innovative robotic arm and implantable surgical solutions that restore
patient quality of life.
Products:
MAKO’s RIO ® Robotic Arm Interactive Orthopedic System coupled with its proprietary
RESTORIS ® Family of Implants, enable surgeons to perform an orthopedic procedure called
MAKOplasty ® for partial knee resurfacing and total hip arthroplasty. The RIO system overcomes
limitations of conventional orthopedic surgeries by providing auditory, visual, and tactile guidance
that, when integrated with the touch and feel of the surgeon’s skilled hand, provides consistently
reproducible precision in partial knee and total hip replacement surgeries.
MAKOplasty Partial Knee Resurfacing is an advanced treatment option designed to relieve
pain and restore range of motion for adults living with early to mid-stage osteoarthritis that has not
progressed to all three compartments of the knee. This procedure offers a less invasive surgery
and a more rapid recovery than total knee arthroplasty.
MAKOplasty Total Hip Arthroplasty is an innovative surgical treatment option for adults living
with non-inflammatory or inflammatory degenerative joint disease. Advanced robotic arm
technology and versatile implants assist surgeons in attaining a new level of accuracy.
Number of Procedures: As of December 31, 2012, approximately 23,000 MAKOplasty
procedures have been performed worldwide.
Intellectual Property Portfolio: MAKO has an intellectual property portfolio of more than 300
licensed or owned patents and patent applications relating to the areas of robotics, tactile (sense
of touch), computer assisted surgery and implants.
Financial Information: MAKO’s stock is publicly traded on the NASDAQ Global Select Market
under the ticker symbol “MAKO” (initial public offering in 2008). Since its inception, MAKO has
raised over $300 million in equity financing to support growth. In 2012, total revenue reached over
$100 million.
© MAKO Surgical Corp. 208578 r00 03/13

Company History:
• MAKO Surgical Corp. founded
November 2004
• FDA clearance of the TGS Robotic Arm System
November 2005
• First MAKOplasty UniCompartmental knee procedure
performed
June 2006
• Initial Public Offering
February 2008
• FDA clearance of RESTORIS MCK Unicompartmental
Knee System
June of 2008
• FDA clearance of the RIO Robotic Arm Interactive
Orthopedic System, and RESTORIS MCK
MultiCompartmental Knee System
November 2008
• Peer reviewed clinical publication, Journal of
Arthroplasty
December 2008
• RIO and RESTORIS MCK Introduction
February 2009
• 1,000 th MAKOplasty procedure performed
March 2009
• Lateral Unicompartmental knee application introduction
for the RIO System
December 2009
• First CE Mark for RIO System granted
January 2010
• FDA clearance of MAKOplasty Total Hip Arthroplasty
February 2010
• First MAKOplasty Total Hip Arthroplasty procedure
performed
October 2010
• 10,000 th MAKOplasty procedure performed
September 2011
• MAKOplasty Total Hip Arthroplasty introduction
September 2011
• RESTORIS PST ® Acetabular Cup and RESTORIS
Tapered Femoral Stem introduction
© MAKO Surgical Corp. 208578 r00 03/13

October 2012
Management Team:
Maurice R. Ferré, M.D., President, CEO and Chairman of the Board
Fritz L. LaPorte, Senior Vice President of Finance and Administration, CFO and Treasurer
Christopher R. Marrus, Senior Vice President of Sales
Ivan Delevic, Senior Vice President of Marketing
Richard Leparmentier, Senior Vice President of Engineering
Duncan H. Moffat, Senior Vice President of Operations
Menashe R. Frank, Esq., Senior Vice President, General Counsel and Secretary
Lawrence T. Gibbons, Senior Vice President of Quality and Regulatory Affairs
Board of Directors:
Maurice R. Ferré, M.D., President, Chairman and CEO, MAKO Surgical Corp.
S. Morry Blumenfeld, Ph.D., Founder, Meditech Advisors; Member of Ziegler MediTech Partners
Christopher C. Dewey, Former Vice-Chairman of the Board of Directors of National Holdings
Corporation
Charles W. Federico, Former President and CEO, Orthofix International
John G. Freund, M.D., Managing Director, Skyline Ventures; Co-founder, Intuitive Surgical, Inc.
Frederic H. Moll, M.D., Co-founder and Former CEO, Hansen Medical, Inc.; Co-founder of
Intuitive Surgical, Inc.
Richard Pettingill, Former President and CEO, Allina Hospitals and Clinics
William D. Pruitt, President of Pruitt Enterprises, LP.
# # #
Media Contacts:
Amy Cook
Sue Siebert
925.552.7893 954.628.0804
amycook@amcpublicrelations.com
ssiebert@makosurgical.com
© MAKO Surgical Corp. 208578 r00 03/13